Niraparib plus temozolomide for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (niraparib and temozolomide) for people with glioblastoma or other gliomas that have come back after standard treatment. Niraparib is a type of drug that may help stop cancer cells from repairing themselves, making temozolomide work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a glioblastoma (a type of brain cancer) or a lower-grade glioma (astrocytoma or oligodendroglioma) that has come back or is getting worse after initial treatment.
- You must have already received standard treatment for your brain tumor (surgery, radiation, and/or chemotherapy like temozolomide).
- You must be able to swallow pills whole without chewing or crushing them.
- You must not have any serious heart problems, bleeding issues, or other uncontrolled medical conditions that would make the trial risky.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether combining three medicines can slow or shrink recurrent glioma (a type of brain tumor). It is for adults whose tumor has come back after standard treatment, with certain genetic tumor markers that may help guide whether you can join.
This trial tests a combination of two drugs, triapine and temozolomide, for people whose glioblastoma has come back after initial treatment. The goal is to see if this combination can help control the tumor.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests whether adding cannabinoid medicine to temozolomide helps people whose glioblastoma (GBM) has returned. It compares temozolomide plus cannabinoids versus temozolomide alone, using blinded treatment so neither you nor the team knows which option you get.
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
Hear when a new Glioma, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.